Om Sai Clinical Research Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 10-12-2024
- Paid Up Capital ₹ 0.10 M
as on 10-12-2024
- Company Age 14 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.25 Cr
as on 10-12-2024
- Revenue 19.39%
(FY 2021)
- Profit 89.65%
(FY 2021)
- Ebitda 1.70%
(FY 2021)
- Net Worth -1.25%
(FY 2021)
- Total Assets -6.78%
(FY 2021)
About Om Sai Clinical Research
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.25 Cr.
Abhay Patkar and Anjali Patkar serve as directors at the Company.
- CIN/LLPIN
U73100PN2010PTC136799
- Company No.
136799
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Jul 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Sangli, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Om Sai Clinical Research?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhay Patkar  | Managing Director | 20-Aug-2010 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Anjali Patkar | Director | 20-Aug-2010 | Current |
Financial Performance and Corporate Structure Insights of Om Sai Clinical Research.
Om Sai Clinical Research Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 19.39% increase. The company also saw a substantial improvement in profitability, with a 89.65% increase in profit. The company's net worth dipped by a decrease of 1.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Om Sai Clinical Research?
In 2021, Om Sai Clinical Research had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aureus Research Private LimitedActive 9 years 5 monthsAbhay Patkar and Anjali Patkar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 10 May 2019 | ₹1.75 Cr | Open |
Others Creation Date: 25 Apr 2018 | ₹2.20 Cr | Open |
Others Creation Date: 09 Sep 2010 | ₹1.30 Cr | Open |
How Many Employees Work at Om Sai Clinical Research?
Unlock and access historical data on people associated with Om Sai Clinical Research, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Om Sai Clinical Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Om Sai Clinical Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
